Construction of Recombinant Plasmid of MicroRNA Targeting Stat3 mRNA and Their Expression in Hepatocellular Carcinoma Cells

ZHANG Yong,LI De-chun,GUO Zi-jian,DAI Sai-min,HUANG Chao-hui,ZHU Dong-ming
2011-01-01
Abstract:Objective To construct and select synthetic MicroRNA targeting Stat3mRNA expressing plasmid that can inhibit Stat3 expression in human hepatocellular carcinoma HepG2 cells.Methods Three pairs of oligos for MicroRNA targeting human Stat3 mRNA and negative control oligo were chemically synthesized.The annealed oligos were inserted into the downstream of linear pcDNA6.2-GW/EmGFP-miR expression vector to construct RNA interference(RNAi) plasmid.The four plasmids(named miR-1,miR-2,miR-3and miR-neg) were transfected into Human HepG2 cells by LipofectamineTM 2000,efficiency of transfection was detected by fluorescence microscopy and FCS.Real-time PCR and Western blot were applied to detect the expression level of Stat3mRNA and protein respectively.Detection of apoptosis was manipulated by FCM.While MTT assay was used to determine proliferation rate of HepG2.Results The recombinant plasmids pcDNA6.2-GW/EmGFP-miR-1,2,3were successfully constructed and the inserted sequence was consfirmed by DNA sequencing.Fluorescence microscopy showed that the transfection efficiency were 76%,73% and 63%.The inhibition ratio of Stat3mRNA was 73.5%,47.2%,and 39.6%.The inhibition ratio of Stat3 protein was 89.1%,71.6%,67.3%.The expression level of Stat3mRNA and protein were the lower in miR-1 transfected HepG2 cells than that of the other miR-,miR-neg or untransfected(P﹤0.01).Meanwhile,in the HepG2 cells,in the miR-1 group,the apoptotic rate significantly increased,and the ability of proliferation was inhibited remarkably,compared with the cells in the negative control group and the untransfected group(P﹤0.01).Conclusion The synthetic MicroRNA plasmid targeting human Stat3mRNA is successfully developed and can be applied to study the affection of interference by synthetic MicroRNA targeting human Stat3mRNA in human hepatocellular carcinoma HepG2 cells.
What problem does this paper attempt to address?